SCHEMBL17674635

SCHEMBL17674635

CC1c2ccccc2CCN1C(=O)Nc1ccccc1F

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TRPM8 Q7Z2W7 3/20 0.63
▸ NPC1 O15118 2/20 0.60
▸ RAB9A P51151 1/20 0.60
▸ KDM4E B2RXH2 2/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.49
▸ TAS1R3 Q7RTX0 1/20 0.49
▸ TAS1R1 Q7RTX1 1/20 0.49
▸ DRD1 P21728 1/20 0.49
▸ POLB P06746 1/20 0.48
▸ KMT2A Q03164 1/20 0.47
▸ GRM5 P41594 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ TAAR1 Q96RJ0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17674734 0.86 SMN1; SMN2 (0.61) TRPM8NPC1RAB9AL3MBTL1DRD1
SCHEMBL17674641 0.85 DRD1 (0.49) TRPM8NPC1RAB9ATAS1R3TAS1R1
SCHEMBL17674598 0.85 DRD1 (0.49) TRPM8NPC1RAB9ATAS1R3TAS1R1
SCHEMBL17674721 0.82 DRD1 (0.47) TRPM8NPC1RAB9ADRD1POLB
SCHEMBL17674644 0.82 DRD1 (0.61) TRPM8NPC1RAB9AL3MBTL1TAS1R3
SCHEMBL23327029 0.82 NPC1 (0.68) TRPM8NPC1RAB9ADRD1POLB
SCHEMBL17674604 0.79 TAS1R3 (0.63) NPC1KDM4EL3MBTL1TAS1R3TAS1R1
SCHEMBL17674691 0.79 DRD1 (0.53) NPC1RAB9ADRD1POLBKMT2A
SCHEMBL17674761 0.79 DRD1 (0.53) NPC1RAB9ADRD1POLBKMT2A
SCHEMBL17674616 0.78 DRD1 (0.67) NPC1TAS1R3TAS1R1DRD1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3204359-B1 TETRAHYDROISOQUINOLINE DERIVATIVES UCB Biopharma SRL (BE) 2020-07-01 — — EP disclosed
US-10105359-B2 Tetrahydroisoquinoline derivatives UCB BIOPHARMA SPRL (BE) 2018-10-23 — — US disclosed
US-20170304292-A1 Tetrahydroisoquinoline Derivatives UCB BIOPHARMA SPRL (BE) 2017-10-26 — — US disclosed
EP-3204359-A1 TETRAHYDROISOQUINOLINE DERIVATIVES UCB Biopharma SPRL (BE) 2017-08-16 — — EP disclosed
WO-2016055479-A1 TETRAHYDROISOQUINOLINE DERIVATIVES UCB BIOPHARMA SPRL (BE) 2016-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170304292-A1 Tetrahydroisoquinoline Derivatives OPRD1, ADRA1D, GPR52 TRPM8 984/4885NPC1 1608/4885RAB9A 1122/4885
US-10105359-B2 Tetrahydroisoquinoline derivatives OPRD1, ADRA1D, GPR52 TRPM8 984/4885NPC1 1608/4885RAB9A 1122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback